FAKTOR-ZERTIFIKAT - BIOGEN IDEC | Market Closed - Börse Stuttgart 20:42:30 28/06/2024 BST | ||
| 2.47 EUR | -0.80% |
|
| Current month | -33.42% | ||
| 1 month | -50.50% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
BIOGEN INC.
Latest news about BIOGEN INC.
More news
| Date | Price | Change |
|---|---|---|
| 28/06/24 | 2.47 | -0.80% |
| 27/06/24 | 2.49 | -22.91% |
| 26/06/24 | 3.23 | +3.19% |
| 25/06/24 | 3.13 | +9.82% |
| 24/06/24 | 2.85 | -9.24% |
Delayed Quote Börse Stuttgart
Last update June 28, 2024 at 08:42 pm
More quotesStatic data
| Product type | Exotic Products |
|---|---|
| Buy / Sell | CALL |
| Underlying | BIOGEN INC. |
| Issuer | J.P. Morgan |
| WKN | JK4G0G |
| ISIN | DE000JK4G0G1 |
| Date issued | 22/03/2024 |
| Strike | 257.3 $ |
| Maturity | Unlimited |
| Parity | 11.27 : 1 |
| Emission price | 10.08 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 30.45 € |
|---|---|
| Lowest since issue | 2.23 € |
| Spread | 0.2 € |
| Spread % | 8.20% |
Company Profile
Biogen Inc. is one of the world's leaders in the design, manufacturing, and marketing of therapeutic products. Net sales break down by source of income as follows:
- sales of medicines (73,7%): for treating multiple sclerosis, chronic psoriasis in adults, rheumatoid arthritis, cancers, etc.;
- royalties (17,2%) ;
- other (9,1%): primarily revenues from partnership agreements.
Sector
-
Consensus: Biogen Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
35
Last Close Price
231.8
USD
Average target price
283.2
USD
Spread / Average Target
+22.14%
- Stock Market
- Certificates
- Certificat
